These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 12796526)

  • 1. Longitudinal outcome of Parkinson's disease patients with psychosis.
    Factor SA; Feustel PJ; Friedman JH; Comella CL; Goetz CG; Kurlan R; Parsa M; Pfeiffer R;
    Neurology; 2003 Jun; 60(11):1756-61. PubMed ID: 12796526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clozapine in Parkinson's disease psychosis: 5-year follow-up review.
    Klein C; Gordon J; Pollak L; Rabey JM
    Clin Neuropharmacol; 2003; 26(1):8-11. PubMed ID: 12567158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Understanding of Psychosis in Parkinson's Disease.
    Ojo OO; Fernandez HH
    Curr Psychiatry Rep; 2016 Oct; 18(10):97. PubMed ID: 27629356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosis in nursing home patients with Parkinson's disease.
    Kang GA; Bronstein JM
    J Am Med Dir Assoc; 2004; 5(3):167-73. PubMed ID: 15115577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease.
    Giladi N; Treves TA; Paleacu D; Shabtai H; Orlov Y; Kandinov B; Simon ES; Korczyn AD
    J Neural Transm (Vienna); 2000; 107(1):59-71. PubMed ID: 10809404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.
    Aarsland D; Larsen JP; Tandberg E; Laake K
    J Am Geriatr Soc; 2000 Aug; 48(8):938-42. PubMed ID: 10968298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial.
    Factor SA; Friedman JH; Lannon MC; Oakes D; Bourgeois K;
    Mov Disord; 2001 Jan; 16(1):135-9. PubMed ID: 11215574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
    Merims D; Balas M; Peretz C; Shabtai H; Giladi N
    Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis.
    Factor SA; Brown D; Molho ES; Podskalny GD
    Neurology; 1994 Mar; 44(3 Pt 1):544-6. PubMed ID: 8145929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hallucinations and psychosis in Parkinson's disease.
    Eng ML; Welty TE
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of behavioural symptoms and dementia in Parkinson's disease.
    Hanagasi HA; Emre M
    Fundam Clin Pharmacol; 2005 Apr; 19(2):133-46. PubMed ID: 15810893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.
    Hack N; Fayad SM; Monari EH; Akbar U; Hardwick A; Rodriguez RL; Malaty IA; Romrell J; Wagle Shukla AA; McFarland N; Ward HE; Okun MS
    PLoS One; 2014; 9(3):e91545. PubMed ID: 24646688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.
    Broadstock M; Ballard C; Corbett A
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):779-86. PubMed ID: 25301532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clozapine and risperidone treatment of psychosis in Parkinson's disease.
    Ellis T; Cudkowicz ME; Sexton PM; Growdon JH
    J Neuropsychiatry Clin Neurosci; 2000; 12(3):364-9. PubMed ID: 10956570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics in Parkinson-sensitive populations.
    Friedman JH; Fernandez HH
    J Geriatr Psychiatry Neurol; 2002; 15(3):156-70. PubMed ID: 12230086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
    Zahodne LB; Fernandez HH
    Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of Pimavanserin in Dementia-Related Psychosis.
    Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
    N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson disease psychosis: Update.
    Friedman JH
    Behav Neurol; 2013 Jan; 27(4):469-77. PubMed ID: 23242358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.